Advertisement

Pharmacokinetics and Pharmacodynamics of Fibrinolytic Agents

  • Carlos Jerjes-SánchezEmail author
  • H. David Rodriguez

Abstract

In this chapter, the historical development, as well as, pharmacokinetics and pharmacological properties of the more frequently used fibrinolytic agents in pulmonary embolism patients, namely streptokinase, alteplase, and tenecteplase are analyzed. The historical development of the first-, second-, and third-generation fibrinolytics has been reviewed. Also, the first pulmonary embolism case using successful thrombolysis with streptokinase, rt-PA, alteplase, and TNK-t-PA is described.

Keywords

Fibrinolytic agents Thrombolysis Alteplase Streptokinase Tenecteplase 

References

  1. 1.
    Thelwell C. Biological standards for potency assignment to fibrinolytic agents used in thrombolytic therapy. Semin Thromb Hemost. 2014;40:205–13.CrossRefPubMedGoogle Scholar
  2. 2.
    Furie F, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.CrossRefPubMedGoogle Scholar
  3. 3.
    Silvain J, Collet JP, Nagaswami C, Beygui F, Edmondson KE, Bellemain-Appaix A, Cayla G, Pena A, Brugier D, Barthelemy O, Montalescot G, Weisel JW. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011;57:1359–67.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Collen D. On the regulation and control of the fibrinolysis. Thromb Haemost. 1980;43:77–89.PubMedGoogle Scholar
  5. 5.
    Tillet WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med. 1933;58:485–502.CrossRefGoogle Scholar
  6. 6.
    Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol. 1941;42:109–16.Google Scholar
  7. 7.
    Christensen LR. Streptococcal fibrinolysis: a proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysis. J Gen Physiol. 1945;28:363–83.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Christensen LR, MacCleod CM. A proteolytic enzyme of serum: characterization, activation and reaction with inhibitors. J Gen Physiol. 1945;28:559–83.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Tillet WS, Sherry S. The effect of streptococcal fibrinolysis (streptokinase) and streptococcal deoxyribonuclease on fibrinous, purulent and sanguinous pleural exudation. J Clin Invest. 1949;28:173–90.CrossRefGoogle Scholar
  10. 10.
    Johnson AJ, McCarthy WR. The lysis of artificially induced clots in man by intravenous of streptokinase. J Clin Invest. 1957;38:1627–43.CrossRefGoogle Scholar
  11. 11.
    Kline DL. Purification and crystallization of plasminogen (profibrinolysin). J Biol Chem. 1953;2404:949–55.Google Scholar
  12. 12.
    Sherry S. The fibrinolytic activity of streptokinase activated human plasmin. J Clin Invest. 1954;35:1054–63.CrossRefGoogle Scholar
  13. 13.
    Sherry S, Fletcher AP, Alkjaersig N, Smyrniotis FE. An approach of intravascular fibrinolysis in the man. Trans Assoc Am Physicians. 1957;70:288–96.PubMedGoogle Scholar
  14. 14.
    Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians. 1958;71:287–96.PubMedGoogle Scholar
  15. 15.
    Fletcher AP, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J Clin Invest. 1959;38:1096–110.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Fletcher AP, Sherry S, Alkjaersig N, Smyrniotis FE, Jick S. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest. 1959;38:1111–9.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Bett JHN, Castaldi PA, Hale GS, Ibist JP, Mclean KH, O´Sullivan EF, Biggs JC, Chesterman CN, Hirsh J, Mcdonald IG, Morgan JJ, Rosembaum M. Australian multicenter trial of streptokinase in acute myocardial infarction. Med J Aust. 1977;1:553–60.Google Scholar
  18. 18.
    Jerjes-Sanchez C, Ramirez-Rivera A, Elizalde GJ, Delgado R, Cicero R, Ibarra-Perez C, Arroliga AC, Padua A, Portales A, Villarreal A, Perez-Romo A. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema. A multicenter trial. Chest. 1996;109:1514–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Browse NL, James DCO. Streptokinase in pulmonary embolism. Lancet. 1964;2:1039–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J. 2007;34:318–27.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Longstaf C, Thelwell C, Whitton C. The poor quality of streptokinase products in use in developing countries. Thromb Haemost. 2005;3:1092–3.CrossRefGoogle Scholar
  22. 22.
    Jerjes-Sanchez C, Ramirez-Rivera A, Garcia ML, Arriaga-Nava R, Valencia-Sanchez S, Rosado-Buzzo A, Pierzo JA, Rosas ME. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:67–9.CrossRefGoogle Scholar
  23. 23.
    Astrup T, Permim PM. Fibrinolysis in the animal organism. Nature. 1947;159:681–2.CrossRefPubMedGoogle Scholar
  24. 24.
    Astrup T, Stage A. Isolation of a soluble fibrinolytic activator from animal tissue. Nature. 1952;170:929.CrossRefPubMedGoogle Scholar
  25. 25.
    Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69:209–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Collen D, Lijnen HR. History of discovery: the tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol. 2009;29:1151–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Rijken DC, Wijngaards G, Zaal-de Jong M, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta. 1979;580:140–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res. 1980;18:815–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981;256:7035–41.PubMedGoogle Scholar
  30. 30.
    Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982;257:2912–9.PubMedGoogle Scholar
  31. 31.
    Rijken DC, Juhan-Vague I, De Cock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med. 1983;101:274–84.PubMedGoogle Scholar
  32. 32.
    Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human extrinsic (tissue-type) plasminogen activator in centigram quantities from a human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemost. 1982;48:294–6.PubMedGoogle Scholar
  33. 33.
    Matsuo O, Rijiken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolism. Nature. 1981;291:590.CrossRefPubMedGoogle Scholar
  34. 34.
    Bergman SR, Fox KAA, Ter-Pogossian MM, Sobel BE, Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science. 1983;220:1181.1183.CrossRefGoogle Scholar
  35. 35.
    Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KAA, DeGeest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984;310:609–13.CrossRefPubMedGoogle Scholar
  36. 36.
    Bounameaux H, Vermylen H, Collen D. Thrombolytic treatment with recombinant tissue-type recombinant activator in a patient with massive pulmonary embolism. Ann Intern Med. 1985;103:64–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Binder BR, Spragg J, Austen KF. Purification and characterization of human vascular plasminogen activator derived from blood vessels perfusates. J Biol Chem. 1979;254:1998–2003.PubMedGoogle Scholar
  38. 38.
    Korninger C, Collen D. Neutralization extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemost. 1981;46:662–5.PubMedGoogle Scholar
  39. 39.
    Ranby M, Bergsdorf N, Nilsson T. Enzymatic properties of one-chain and two-chain forms of tissue plasminogen activator. Thromb Res. 1982;27:175–83.CrossRefPubMedGoogle Scholar
  40. 40.
    Ranby M, Bergsdorf N, Pohl G, Wallen P. Isolation of two variants of native one-chain tissue plasminogen activator. FEBS Lett. 1982;146:289–92.CrossRefPubMedGoogle Scholar
  41. 41.
    Thorsen S, Glas-Greenwalt P, Astrup T. Differences in the binding of fibrin to urokinase and tissue plasminogen activator. Thromb Diath Haemorrh. 1972;28:65–74.PubMedGoogle Scholar
  42. 42.
    Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem. 1982;257:2920–5.PubMedGoogle Scholar
  43. 43.
    Camiolo SM, Thorsen D, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med. 1971;138:277–80.CrossRefPubMedGoogle Scholar
  44. 44.
    Wallen P. Thrombosis and urokinase. In: Paoletti R, Sherry S, editors. Activation of plasminogen with urokinase and tissue activator. London: Academic; 1977. p. 91–102.Google Scholar
  45. 45.
    Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta. 1982;704:461–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Nieuwenhuizen W, Verheijen JH, Vermond A, Chang GTG. Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2. Biochim Biophys Acta. 1983;775:531–3.CrossRefGoogle Scholar
  47. 47.
    Nieuwenhuizen W, Vermond A, Voskuilen M, Traas DW. Identification of the site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta. 1983;748:86–92.CrossRefPubMedGoogle Scholar
  48. 48.
    Radcliffe R, Heinze T. Stimulation of tissue plasminogen activator by denatured proteins and fibrin clot: a possible additional role for plasminogen activator. Arch Biochem Biophys. 1981;211:750–61.CrossRefPubMedGoogle Scholar
  49. 49.
    Suenson E, Lützen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feedback mechanism in fibrinolysis. Eur J Biochem. 1984;140:513–22.CrossRefPubMedGoogle Scholar
  50. 50.
    Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of human plasma protein with affinity for the lysine-binding site of plasminogen. Role in the regulation of fibrinolysis and identification as histine-rich glycoprotein. J Biol Chem. 1980;255:10214–22.PubMedGoogle Scholar
  51. 51.
    Holvoet P, Lijnen HR, Collen D. Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies. Eur J Biochem. 1986;158:173–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Rijken DC, Groeneveld E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem. 1986;261:3098–102.PubMedGoogle Scholar
  53. 53.
    Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978;84:573–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Van de Werf FJ. The ideal fibrinolytic: can drug design improve clinical results? Eur Heart J. 1999;20:1452–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Jerjes-Sánchez C, Gutiérrez-Fajardo P, Ramírez-Rivera A, García ML, Hernández CHG. Acute right ventricular myocardial infarction secondary to massive pulmonary embolism. Arch Inst Cardiol Mex. 1995;65:65–73.PubMedGoogle Scholar
  56. 56.
    Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy for acute myocardial infarction. Clin Pharmacokinet. 2002;41:1229–45.CrossRefPubMedGoogle Scholar
  57. 57.
    Goldhaber SZ, Come PC, Lee RT, Brauwald LT, Parker JA, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, de Silva AM T, Mogtader A, McDonough TJ. Alteplase versus heparin in acute pulmonary embolism; randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507–11.CrossRefPubMedGoogle Scholar
  58. 58.
    Keyt B, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670–4.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TAP. Circulation. 1995;92:3032–40.CrossRefPubMedGoogle Scholar
  60. 60.
    Cannon CP, McCabe CH, Gibson CM, et al. and the TIMI 10A Investigators. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Rangin Trial. Circulation 1997;95:351–6.Google Scholar
  61. 61.
    Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost. 1998;79:134–9.PubMedGoogle Scholar
  62. 62.
    DeMarco E, Rebuzzi AG, Quaranta G, et al. Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction. Eur Heart J. 1998;19(Abstr Suppl):563.Google Scholar
  63. 63.
    Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial. Circulation. 1998;98:2805–14.CrossRefPubMedGoogle Scholar
  64. 64.
    Caldicott D, Parasivam S, Harding J, Edwards N, Bochner F. Tenecteplase for massive pulmonary embolus. Resuscitation. 2002;55:2011–3.CrossRefGoogle Scholar
  65. 65.
    Sze DY, Carey MBL, Razavi MK. Treatment of massive pulmonary embolus with catheter-directed tenecteplase. J Vasc Interv Radiol. 2001;12:1456–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Noorman F, Rijken DC. Regulation of tissue-type plasminogen activator concentrations by clearance via the mannose receptor and other receptors. Fibrinol Proteol. 1997;11:173–86.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Instituto de Cardiologia y Medicina Vascular, TEC SaludSan Pedro Garza GarciaMexico
  2. 2.Escuela de Medicina, Tecnológico de MonterreySan Pedro Garza GarciaMexico
  3. 3.Unidad de Investigacion Clinica en Medicina SCMonterreyMexico
  4. 4.Research Studies Coordinator, Centro de Investigacion Basica y Transferencia, Hospital Zambrano-Hellion, Escuela de Medicina y Ciencias de la SaludTecnológico de MonterreyMonterreyMexico

Personalised recommendations